All News

Top news of the day from across the health care landscape.

Officials with the FDA issued a statement to clarify data accuracy issues with recently-approved gene therapy Zolgensma (onasemnogene abeparvovec-xioi, AveXis), a product intended to treat spinal muscular atrophy (SMA) in children under 2 years old.

Officials with the FDA are assessing data accuracy issues related to Zolgensma, but have no major concerns about the spinal muscular atrophy treatment remaining on the market.

An analysis of previous studies of children and young adults with ADHD has quantified the extent to which stimulant treatment reduces the development of mood disorders, problems in school, conduct disorders, substance use disorders, and other problems.

The opioid epidemic has become widespread throughout the country, and it is considered a top public health priority.

Effective patient-provider communication is critical to the healing process and it begins the moment the patient makes contact with the staff and continues even after the patient fills his prescription at the pharmacy.

Research could lead to the development of new cancer treatments to stop tumor growth.

Top news of the day from across the health care landscape.

Permethrin, an insecticide of the pyrethroid family, is used against mites, ticks, and other insects.

A patient presents with dizziness and is looking for ear wax treatment, but the cause is much more serious than expected.

Pexidartinib (Turalio, Daiichi Sankyo) is indicated for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Top news of the day from across the health care landscape.

Researchers find anticholinergic drugs may cause vascular dementia.

The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigourous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.

Pre-exposure prophylaxis (PrEP) can reduce the risk of HIV infection in individuals at high risk.

The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigorous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.

Officials with the FDA have granted approval to pexidartinib (Turalio, Daiichi Sankyo) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.

It is prudent for pharmacists to stay current with these therapies and prevention strategies, as they are well-positioned to educate and support patients in their illness.

A study by the CDC has made several findings around injection practices and sexual behaviors among HIV-positive persons who inject drugs.

With rapid growth, health system specialty pharmacies are more than likely to run into several operational pain points.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Pembrolizumab (Keytruda, Merck) plus chemotherapy met the primary endpoint of pathological complete response in patients with triple-negative breast cancer in a phase 3 study.

The findings represent the first positive phase 2b study of a personalized cancer vaccine in patients with high-risk melanoma.

With specialty pharmacy emerging as the fastest growing segment of the pharmacy industry, health systems have to address a key question: can you scale for it?

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Announced by the HHS and FDA, the plan seeks to safely import medications that would provide a cost savings to consumers, but some pharmacy and other health care professionals have expressed concerns.

Study provides the longest available follow-up on the survival of patients with advanced melanoma, renal cell carcinoma, and non-small cell lung cancer treated with nivolumab.